Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q04900
UPID:
MUC24_HUMAN
Alternative names:
Endolyn; Multi-glycosylated core protein 24
Alternative UPACC:
Q04900; B4DQ85; E1P5E7; E1P5E8; E1P5E9; O95413; Q5JSU6; Q9BPV0; Q9NR26
Background:
Sialomucin core protein 24, also known as Endolyn or Multi-glycosylated core protein 24, plays a pivotal role in various biological processes. It is instrumental in hematopoiesis, facilitating the adhesion of CD34(+) cells to the stroma and modulating their proliferation. Additionally, it influences the migration of umbilical cord blood CD133+ cells through the CXCL12/CXCR4 axis, and is implicated in prostate cancer metastasis and myogenesis by enhancing cell motility and promoting myoblast fusion into myotubes.
Therapeutic significance:
The association of Sialomucin core protein 24 with autosomal dominant deafness, 66, underscores its potential as a target for therapeutic intervention. Understanding the role of Sialomucin core protein 24 could open doors to potential therapeutic strategies, particularly in the treatment of sensorineural hearing loss and possibly in cancer metastasis and muscle regeneration.